Diabetes Drug & Migraine Relief: Brain Pressure Link
- A study presented at the European Academy of Neurology (EAN) Congress 2025 indicates that liraglutide, a medication typically used for diabetes, significantly reduced migraine frequency in participants.
- The study, conducted at the headache Center of the University of Naples "Federico II," involved 26 adults who were obese and experienced chronic migraine, defined as 15 or...
- While the participants' body-mass index saw a slight decrease,researchers determined that weight loss was not the primary factor in the reduction of migraine days.
Could a diabetes drug unlock migraine relief? A recent study reveals that liraglutide, typically used for diabetes, substantially reduces the frequency of migraine headaches, offering hope for a new treatment approach. Researchers observed a reduction of over 50% in migraine days, leading them to focus on the drug’s impact on brain pressure, not weight loss. The study, conducted in naples, involved obese individuals experiencing chronic migraines, offering compelling data on the potential of pressure modulation for migraine treatment. News Directory 3 explores the exciting link between diabetes medication and secondary_keyword in this developing story.Discover what’s next in migraine management and treatment.
Diabetes drug Shows Promise for Migraine Treatment
Updated June 21, 2025
A study presented at the European Academy of Neurology (EAN) Congress 2025 indicates that liraglutide, a medication typically used for diabetes, significantly reduced migraine frequency in participants. The research focused on the drug’s ability to lower brain fluid pressure.
The study, conducted at the headache Center of the University of Naples “Federico II,” involved 26 adults who were obese and experienced chronic migraine, defined as 15 or more headache days each month. Participants taking liraglutide reported an average of 11 fewer headache days per month. Their scores on the Migraine Disability Assessment test also decreased by 35 points, suggesting notable improvements in their ability to function at work, in academic settings, and socially.
While the participants’ body-mass index saw a slight decrease,researchers determined that weight loss was not the primary factor in the reduction of migraine days. They hypothesize that the drug’s impact on pressure modulation is the key to its effectiveness.
Dr. Simone Braca, the lead researcher, noted that most patients experienced improvements within two weeks, with a sustained benefit throughout the three-month study. he also pointed out that the weight loss observed was not statistically significant.
The study excluded participants with papilledema and sixth nerve palsy to rule out idiopathic intracranial hypertension (IIH).researchers believe that even subtle increases in intracranial pressure can contribute to migraine attacks. Liraglutide and similar drugs have shown effectiveness in treating IIH by reducing cerebrospinal fluid secretion.
“We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide,” Dr. Braca explained. “That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway.”
Some participants experienced mild gastrointestinal side effects, such as nausea and constipation; though, these issues did not lead to anyone discontinu